DB05643InvestigationalProtein Based Therapies
IRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors.Curator reviewed
- Also known as
- Cytokine-based biologic agent IRX-2
- Code names
- IRX-2
Resolves to
Compound
What you can answer from here — as of September 17, 2023
Which companies are running trials of IRX-2, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account